Literature DB >> 9207412

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis.

F Cervantes1, A Pereira, J Esteve, M Rafel, F Cobo, C Rozman, E Montserrat.   

Abstract

To contribute to a better knowledge of the prognosis of idiopathic myelofibrosis (IM), the prognostic value of the presenting features in 106 patients diagnosed with IM at a single institution during a 21-year period was retrospectively analysed. Median survival was 59.4 months (95% CI 40.7-75.4). Using univariate analysis, age > 64 years, constitutional symptoms (fever, night sweats, weight loss), Hb < 10 g/dl, circulating blasts (> or= 1%), and serum LDH > 3 times upper normal level were associated with a significantly shorter survival; male sex, platelet count < 100 x 10(9)/l, blood percentage of immature granulocytes (excluding blasts), low cholesterol levels and advanced marrow histological stage had borderline significance. Using multivariate study, only age > 64 years, constitutional symptoms, Hb < 10 g/dl, and circulating blasts retained their prognostic relevance. The latter three variables confirmed their predictive value in patients above and below the series median age, and were able to identify two groups of patients: a low-risk group of 67 patients with none or one bad prognostic factor, in whom IM had an indolent course (median survival 98.8 months, 95% CI 68.7-127.6), and a high-risk group, including 39 patients with two or three factors, with a more aggressive disease (median survival 20.6 months, 95% CI 10-28.2). Finally, the application of two recently proposed scoring systems (in which three prognostic groups are considered) was unable to separate intermediate- from high-risk patients.

Entities:  

Mesh:

Year:  1997        PMID: 9207412     DOI: 10.1046/j.1365-2141.1997.782714.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan.

Authors:  Katsuto Takenaka; Kazuya Shimoda; Naoyuki Uchida; Taizo Shimomura; Koji Nagafuji; Tadakazu Kondo; Hirohiko Shibayama; Takehiko Mori; Kensuke Usuki; Taichi Azuma; Yutaka Tsutsumi; Junji Tanaka; Hitomi Dairaku; Keitaro Matsuo; Keiya Ozawa; Mineo Kurokawa; Shunya Arai; Koichi Akashi
Journal:  Int J Hematol       Date:  2016-10-19       Impact factor: 2.490

3.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

4.  Contribution of comorbidities and grade of bone marrow fibrosis to the prognosis of survival in patients with primary myelofibrosis.

Authors:  Danijela Lekovic; Mirjana Gotic; Maja Perunicic-Jovanovic; Ana Vidovic; Andrija Bogdanovic; Gradimir Jankovic; Vladan Cokic; Natasa Milic
Journal:  Med Oncol       Date:  2014-02-06       Impact factor: 3.064

Review 5.  Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.

Authors:  William J Hogan; Mark R Litzow; Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2007-02       Impact factor: 3.952

6.  Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients.

Authors:  T Okamura; N Kinukawa; Y Niho; H Mizoguchi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

7.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

8.  The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  Br J Haematol       Date:  2013-03-11       Impact factor: 6.998

9.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

10.  Outcome of transplantation for myelofibrosis.

Authors:  Karen K Ballen; Smriti Shrestha; Kathleen A Sobocinski; Mei-Jie Zhang; Asad Bashey; Brian J Bolwell; Francisco Cervantes; Steven M Devine; Robert Peter Gale; Vikas Gupta; Theresa E Hahn; William J Hogan; Nicolaus Kröger; Mark R Litzow; David I Marks; Richard T Maziarz; Philip L McCarthy; Gary Schiller; Harry C Schouten; Vivek Roy; Peter H Wiernik; Mary M Horowitz; Sergio A Giralt; Mukta Arora
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-30       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.